

STRATEGIES FOR TEST METHOD VALIDATION OF DRUG DELIVERY PLATFORMS

In this article, Deepu Asok, Manager, Small Molecule Portfolio Ops & Analytics, at Pfizer, discusses the importance of test method validation for drug-device combination product development and how a common mistake is to design the validation process for a specific device rather than to accommodate the potential variety of a device platform.

With the recent rise in use of biologics for treating chronic diseases, the relevance and application of injectable drug delivery systems are on the rise. The global injectable drug delivery devices market reached a value of nearly US\$39.9 billion (£32.1 billion) in 2022 and is expected to grow to \$58.1 billion by 2027 at a rate of 7.5%.¹

As more therapies shift towards self-administration in an at-home setting, the need for innovative injection devices is on the rise.

This rising demand has forced both device and drug manufacturers to think in terms of delivery platforms instead of one-off delivery devices. However, this means that manufacturers must become creative when designing their studies to gather evidence about the safety and effectiveness of these delivery platforms. A key element to ensure the success of those studies is the test methods used to verify the safety and efficacy of the devices. The strength of the data rests upon the foundation of the test method validation (TMV), which establishes that the test methods are robust, repeatable and fit for purpose.

WHAT IS TEST METHOD VALIDATION?

When a design is established based on specified design inputs, it becomes the responsibility of the device manufacturer to confirm that the design outputs meet the predefined acceptance criteria. The aim of design verification is to ascertain that design outputs not only fulfil the requirements detailed in the design input document(s) but also evaluate the efficacy of risk controls. Pursuant to this, test methods function as the tools for generating data for design

“When a design is established based on specified design inputs, it becomes the responsibility of the device manufacturer to confirm that the design outputs meet the predefined acceptance criteria.”

verification tasks. Similar to any tool, the data gathered from them are only as reliable as the tool itself. If a tool is defective, it will produce inaccurate measurements, which, in turn, will lead to incorrect conclusions. Therefore, it is essential to validate test methods to guarantee repeatable and reproducible results; this is vital for the success of any product development project.

A standard TMV process involves designing a study wherein multiple operators conduct a study where they gather test data using the proposed test method. The study will also involve multiple trials on the same (in the case of non-destructive tests) or similar (in the case of destructive tests) test articles. Once gathered, the test results are analysed for variability within the same operator's data and between that collected by different operators. As long as the total variability falls within the range of the acceptable variability limits previously established, the method is deemed suitable for gathering design verification data to be used in the submission.

Conducting TMV studies for multiple test methods can involve a significant amount of time and resources. The whole process involves significant planning and preparation, including standalone supporting documentation, such as TMV plans, protocols and summary reports.



Deepu Asok
Manager, Small Molecule Portfolio
Ops & Analytics
T: +1 785 236 9331
E: deepu.asok@pfizer.com

Pfizer Inc.
375 N Field Dr
Lake Forest
IL-60045
United States

www.pfizer.com

“One of the common mistakes that people make when conducting TMV is that they design their validation plans around the product, not the platform.”

A common mistake lies not in the execution of such studies but rather in not thinking holistically about the larger needs of the organisation and future device platforms.

THINK IN PLATFORMS, NOT PRODUCTS

One of the common mistakes that people make when conducting TMV is that they design their validation plans around the product, not the platform. For example, executing the TMV using a specific prefilled syringe (PFS) or autoinjector design that the developer plans to file for the immediate submission. Then, a few months later, they realise that there is a new PFS design that needs TMV as well. However, it may not be possible to use the previous TMV study, as the validated range is specific to the product that was included in that study and the new product's performance data falls outside that validated range.

In this case, there is no other choice but to repeat the TMV study for the same test methods, but this time with the new product design. This could require a significant investment in terms of time and effort that could have been saved if the TMV was strategically designed to cover future design variations within that injectable device category. After all, all PFSs must adhere to the same test methods prescribed in ISO standards, such as ISO 11040, 7886 or 11608.




Figure 1: Scenario 1 shows the limitations in the validated data range when using just a single product or part for TMV studies. Scenario 2 shows how using several parts or products within a TMV study provides a wider validated range for the test method.

INCLUDE PRODUCT VARIANTS IN THE ORIGINAL TMV STUDY

To avoid this problem of having to repeat TMV studies, try to include multiple product variations within the same study. For example, if there is a 5, 10 and 15 mL version of a syringe, think of ways to design a test method that be used for all these variants. As shown in Figure 1, this can extend the validated range of a test method. Including at least two more product variants, one for a lower data range and one for a higher data range, will establish a validated test method that can be used for multiple design verification studies in the future.

INCLUDING CHALLENGE PARTS IN TMV STUDIES

As discussed, it would be beneficial to include multiple product variations within the same TMV study to avoid the need for future repetition of work. However, during early studies, it may be challenging to obtain different variations of the injectable device. In such cases, the concept of challenge parts can be invaluable.

Challenge parts are custom-engineered test articles that simulate the form and mechanical function of the product family under investigation. For example, when validating the break-loose and extrusion force of a PFS with only one available

variant, an engineered sample can be created to replicate the syringe's form and function, such as a piston-barrel system. This sample can then be designed to encompass a broader range of break-loose and extrusion forces than the product intended for verification.

By adopting this challenge parts approach, the validated range of the test method can be extended, while also incorporating the final product to be tested during design verification testing in the comprehensive validation study (Figure 2). However, it is important to ensure that the product that will ultimately be tested during design verification testing is included when conducting TMV studies with challenge parts.

DESIGNING UNIVERSAL TEST FIXTURES

One of the key elements of a test method is the test fixture that is used to hold or manipulate the test article. Instead of designing a fixture around the specific dimensions of an injectable device, it is valuable to develop a design that can accommodate potential variations of future designs. For example, a PFS can come in different shapes, materials and form factors. It could be one with a Luer or non-Luer tip design, one with a glass flange or an add-on flange adaptor, or one with or without a safety device. It is possible to design a fixture that can be adjusted to accommodate these variations without significantly altering the physics of the testing mechanism.

This can be achieved either by designing fixtures that can be adjusted to accommodate the variations in form factor or by using replaceable adapters that can be swapped in and out based on the changes in device design. For example, one of the most common test methods for PFSs is needle-shield removal force, which is often tested by constraining the syringe body and using a pull fork to




Figure 2: Scenario 1 shows the limitations in the validated data range when using just a single product or part for TMV studies. Scenario 2 shows how using engineered challenge parts within a TMV study provides a wider validated range for the test method.

"Embracing a strategic approach to TMV by focusing on platforms rather than individual products can significantly enhance the efficiency and adaptability of the validation process."

CONCLUSION

Embracing a strategic approach to TMV by focusing on platforms rather than individual products can significantly enhance the efficiency and adaptability of the validation process. By adopting strategies such as designing universal fixtures, incorporating challenge parts and leveraging existing test

methods, manufacturers can reduce the development cycle time for drug delivery devices. This accelerated development ultimately enables them to bring life-changing therapies to patients more quickly, improving patient outcomes and addressing urgent healthcare needs while staying ahead in the rapidly evolving world of injectable drug delivery systems.

ABOUT THE COMPANY

Pfizer is a global pharmaceutical corporation headquartered in New York, with its research headquarters in Groton (CT, US). Pfizer is among the world's largest pharma companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004.

REFERENCE

1. "Reportlinker.com announces the release of the report: *Injectable Drug Delivery Devices Global Market Report 2023*". Press Release, Reportlinker.com, February 10, 2023.

ABOUT THE AUTHOR

Deepu Asok is Manager, Small Molecule Portfolio Ops & Analytics, at Pfizer, with over nine years of experience in combination product development, focusing on injectable drug delivery systems. His expertise covers development of needle-based injection systems, including PFSs, pens, autoinjectors and wearable injectors, and the test method validation for parenteral drug delivery systems. Currently, he manages the portfolio operations for Pfizer's value-add and innovative small molecule portfolio.

SAVE THE DATE

13TH ANNUAL

PODD

PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY

OCTOBER 16-17, 2023 • BOSTON

WWW.PODDCONFERENCE.COM